Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients
Abstract
The authors treated 11 treatment-resistant schizophrenic patients with steadily increasing doses of haloperidol to determine the therapeutic range of plasma concentrations in such patients. Six patients responded, usually within a few weeks of treatment and at doses of 50 mg/day or less; plasma concentrations ranged between 17 and 42 ng/ml. Five patients were unresponsive, despite treatment for 13-22 weeks, doses of haloperidol of 180-270 mg/day, and plasma concentrations of 51- 225 ng/ml. Doses greater than 150 mg/day appear unnecessary, because lesser doses generally provide plasma concentrations of 20-50 ng/ml. Failure to respond within 2 months of reaching such doses or plasma concentrations augurs for continued lack of response.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
